Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
European Radiology|December 2, 2020
Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?Nicolai Alexander Huebner, Stephan Korn, Irene Resch, et al.
Scientific Reports|June 21, 2026
UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancerAnita Csizmarik, Áron Soós, Melinda Váradi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 5, 2023
Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [68Ga]Ga-PSMA-11 PET/CT StudyKilian Kluge, Holger Einspieler, David Haberl, et al.
BJU International|April 22, 2020
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancerTibor Szarvas, Anita Csizmarik, Tamás Fazekas, et al.
Wiener Klinische Wochenschrift|June 4, 2025
Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer : Joint statement of the Austrian Society of Nuclear Medicine and Theranostics and the Austrian Society of Urology and AndrologySiroos Mirzaei, Gregor Schweighofer-Zwink, Heidemarie Ofner, et al.
Urologic Oncology|January 19, 2020
Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patientsJudith Stangl-Kremser, Andrea Mari, Rodrigo Suarez-Ibarrola, et al.
BJU International|June 25, 2021
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysisKeiichiro Mori, Hadi Mostafaei, Reza Sari Motlagh, et al.
European Urology Oncology|February 26, 2026
Positron Emission Tomography/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate CancerHeidemarie Ofner, Holger Einspieler, Marius Ozenil, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 21, 2018
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancerBernhard Grubmüller, Daniela Senn, Gero Kramer, et al.
Current Oncology (Toronto, Ont.)|September 30, 2021
Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate CancerTim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, et al.
Pageof 12